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Abstract
Background: Insulin resistance has been recognized as the most significant predictor of further development of
type 2 diabetes mellitus (T2DM). Here we investigated the effect of a heat shock protein (HSP) co-inducer, BGP-
15, on insulin sensitivity in different insulin-resistant animal models and compared its effect with insulin se-
cretagogues and insulin sensitizers.
Methods: Insulin sensitivity was assessed by the hyperinsulinemic euglycemic glucose clamp technique in
normal and cholesterol-fed rabbits and in healthy Wistar and Goto–Kakizaki (GK) rats in dose-ranging studies.
We also examined the effect of BGP-15 on streptozotocin-induced changes in the vasorelaxation of the aorta in
Sprague–Dawley rats.
Results: BGP-15 doses of 10 and 30mg/kg increased insulin sensitivity by 50% and 70%, respectively, in cholesterol-
fed but not in normal rabbits. After 5 days of treatment with BGP-15, the glucose infusion rate was increased in a
dose-dependent manner in genetically insulin-resistant GK rats. The most effective dose was 20mg/kg, which
showed a 71% increase in insulin sensitivity compared to control group. Administration of BGP-15 protected against
streptozotocin-induced changes in vasorelaxation, which was similar to the effect of rosiglitazone.
Conclusion: Our results indicate that the insulin-sensitizing effect of BGP-15 is comparable to conventional
insulin sensitizers. This might be of clinical utility in the treatment of T2DM.
Introduction
Insulin resistance plays amajor role in the developmentof prediabetes and overt type 2 diabetes (T2DM).1 Fur-
thermore, clinical and experimental evidence suggests that
both diabetes and insulin resistance cause endothelial dys-
functions, which may diminish the antiatherogenic role of
the vascular endothelium.2–4 Diabetic endothelial dysfunc-
tion is synonymous with decreased endothelium-dependent
vasorelaxation to acetylcholine.5 A recent large randomized
clinical study of patients with stable coronary artery disease
and T2DM observed that addition of an insulin-sensitizing
drug, a thiazolidinedione or metformin, reduced peripheral
artery disease, revascularization surgery, and leg amputa-
tions—even when adjusting for improved glycemic control.6
The peroxisome proliferator-activated receptor-g (PPAR-g)
agonist the thiazolidinediones (TZDs), so-called insulin sen-
sitizers, enhance insulin action in muscle and fat tissues. The
major side effect, seen with troglitazone, the first TZD, is
liver damage. Because of this dangerous side effect, the Food
and Drug Administration (FDA) removed troglitazone from
the market. Two other glitazones, pioglitazone and rosigli-
tazone, cause weight gain and fluid retention7; moreover,
rosiglitazone is thought to increase the risk of cardiovascular
events.8 The side effects and the necessity for a safe and
effective insulin sensitizer encourage development of com-
pounds that improve insulin sensitivity through other
mechanisms.
BGP-15 [O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic acid],
a hydroxylamine derivative, does not belong to the glitazone
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family. Receptor binding experiments with BGP-15 do not
interfere with ligand-inducible PPAR-a, -g, or -d signaling.9,10
The insulin-sensitizing effect of BGP-15 in ob/ob mice acti-
vates HSP72 in skeletal muscles and prevents c-jun amino-
terminal kinase ( JNK) phosphorylation and subsequent
insulin resistance.11 Furthermore, our previous results indi-
cate that BGP-15 may have additional cardiovascular pro-
tective activity, i.e., it prevented ischemia/reperfusion-
induced heart injury and restored vascular responsiveness
in insulin resistance.12–14 Recent studies demonstrate that
BGP-15 confers protection against rapid pacing-induced at-
rial fibrillation in a Drosophila melanogaster model of cardiac
arrhythmias.12,15
The aim of this series of experiments was to assess the
insulin-sensitizing effect of BGP-15 alone, and in combination
as well, in comparison with oral antidiabetics such as met-
formin, rosiglitazone, and glibenclamide. Furthermore, we
studied the therapeutic effect of BGP15 and rosiglitazone on
vasorelaxation induced by acetylcholine in aortic preparations
isolated from streptozotocin (STZ)-induced diabetic rats.
Materials and Methods
Experimental animals
Adult, male, white New Zealand rabbits, weighing 3–
3.5 kg, adult male Wistar and Goto–Kakizaki (GK) rats
weighing 220–320 grams and male Sprague–Dawley rats
weighing 270–290 grams (aged 9–14 weeks), housed in an
animal room (12-hr light/dark periods a day, temperature of
22–25C, humidity of 50–70%) and fed commercial labora-
tory chow and tap water ad libitum were used after a 2-week
adaptation period.
Food was withdrawn at least 12 hr prior to commence-
ment of experiments to determine insulin sensitivity. A bolus
injection of STZ 50mg/kg intravenously (i.v.) was adminis-
tered via tail vein 12 weeks before use.
Preparation of isolated thoracic aorta
Male Sprague–Dawley rats were anesthetized with so-
dium pentobarbital (Nembutal, Sigma, 60mg/kg). After
thoracotomy, the thoracic aorta was removed and placed in
ice-cold Krebs solution and continuously aerated with 95%
O2, 5% CO2. The descending thoracic aorta was cut into rings
approximately 5mm in length. Ring preparations (n = 4)
were set up in parallel for isometric tension measurement by
maintaining the tissues under a resting preload tension of 2
grams, in 10-mL organ baths (thermostatically controlled for
37 – 0.2C) containing Krebs–Henseleit solution (pH 7.4) and
maintained under oxygenation at 37C. Precontraction of the
aorta was induced by phenylephrine. This maximum con-
striction was previously determined by increasing dose of
the a-adrenergic agonist. Maximum vasorelaxation was ob-
tained by increasing the dose of acetylcholine to the pre-
contracted vascular preparation. Tension measurement was
carried out with Isosys System (EXP-D isolated organ am-
plifier, AIF-01 computer interface and IBM-compatible per-
sonal computer Experimetria Ltd., Budapest).
Hyperinsulinemic euglycemic glucose clamp
Whole-body insulin sensitivity was determined by hyper-
insulinemic euglycemic glucose clamp (HEGC) method as de-
scribed.16 Human regular insulinwas infused at a constant rate
(13–15mU/kgpermin, Actrapid;NovoNordisk, Copenhagen,
Denmark) via one of the venous catheters over 120min. This
insulin infusion rate yielded plasma insulin immunoreactivity
of 100– 5mU/mL in the steady state. Blood samples (0.2mL)
were taken from the arterial cannula for blood glucose con-
centration measurement at 10-min intervals. Blood glucose
concentrationwasmaintained constant (5.5– 0.5mmol/L) by a
variable rate of glucose infusion via the second venous cannula.
When blood glucose had stabilized for at least 20–30min, this
condition was defined as the steady state. In this state, addi-
tional blood samples (0.3mL) were taken for plasma insulin
determination three times at 10-min intervals. The glucose in-
fusion rate (mg/kg per min) during the steady state was the
measure of glucose disposal characterizing insulin sensitivity.
Effect of BGP-15 on insulin sensitivity in normal
and cholesterol-fed rabbits
The rabbits were randomized into two groups. One group
of the animals was continued to be fed normal rabbit chow,
whereas the other group was fed chow enriched with 1.5%
cholesterol over a period of 8 weeks. Each group was di-
vided into six treatment groups (n= 6); one of them was
untreated (without treatment) and the others were treated
with BGP-15 at 5, 10, 20, 30, or 50mg/kg per os, once a day
for 5 days. BGP-15 was provided by N-Gene Research La-
boratories Ltd. (Budapest, Hungary).
Effect of BGP-15, rosiglitazone and metformin on
insulin sensitivity in healthy Wistar and in GK rats
The experiments were carried out with male Wistar and GK
rats. Oral daily doses of BGP-15 (5–30mg/kg), rosiglitazone
(2mg/kg Avandia, SmithKline Beecham plc, Brentford Mid-
dlesex, UK), metformin (100mg/kg, Adimet, Ratiopharm,
Hungary), and distilled water (control group) were applied for
5 days. Insulin sensitivity was assessed by HEGC prior to and
at the end of the treatment period 4–6hr after the last BGP-15
dose. Four groups were used to test the effect of BGP-15 (5, 10,
20, and 30mg/kg) by the HEGC procedure, whereas two
separate groups were used to test the effect of rosiglitazone
(2mg/kg) and metformin (100mg/kg) by this method. The
doses of these latter drugs were selected as described.17
Effect of BGP-15 on insulin sensitivity in
combination with a sulfonylurea antidiabetic
drug in GK rats
The animals were divided into six treatment groups of
seven animals each. Animals were treated once a day orally
with distilled water (control group), BGP-15 (3, 10, and
30mg/kg) alone, glibenclamide (1mg/kg Gilemal, Pan-
nonPharma, Hungary) alone, and BGP-15 (10mg/kg) in
combination with glibenclamide (1mg/kg) for 5 days. Con-
trol rats received 1.0mL of distilled water. Insulin sensitivity
was assessed by HEGC prior to and at the end of treatment
period 4–6 hr after the last BGP-15/glibenclamide dose.
The effects of BGP-15 on ex vivo relaxation of aorta
obtained from normal and STZ-diabetic rats
STZ-treated Sprague–Dawley rats were considered dia-
betic and retained for experiments if their blood glucose
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concentration was higher than 20mmol/L. BGP-15 (in
doses of 20 and 50mg/kg), and rosiglitazone (4mg/kg)
were given to STZ diabetic rats orally over 5 days. Age-
matched, saline-treated, male Sprague–Dawley rats served
as controls.
Statistical analysis
The data were analyzed with one-way analysis of variance
(one-way ANOVA) followed by the Student t-test modified
according to the Bonferroni method for repeated measures.18
The comparisons between treatment groups were calculated
with one-way ANOVA pairwise analysis. Differences were
considered statistically significant at P < 0.05.
Results
Insulin-sensitizing effects of BGP-15 in normal
and cholesterol-fed rabbits
Repetitive oral doses of BGP-15 (once a day) induced a
significant increase in insulin sensitivity during 5-day treat-
ments with 10, 20, 30, and 50mg/kg of BGP-15, respectively,
in cholesterol-fed but not in normal rabbits. BGP-15 doses of
10 and 30mg/kg were the most effective doses because these
showed a 50% and a 70% increase in insulin sensitivity, re-
spectively. The lowest dose studied, 5mg/kg per day, had a
moderate effect, but it did not reach the level of statistical
significance (Fig. 1).
Effect of BGP-15, rosiglitazone, and metformin
on insulin sensitivity in GK rats
All of the applied doses of BGP-15 showed a significant
improvement of insulin sensitivity, which was dose-dependent
up to the level of 20mg/kg in genetically insulin-resistant
GK rats. The most effective dose observed at 20mg/kg of
BGP-15 showed a 71% increase in glucose infusion rate after
5 days of treatment. While BGP-15 improved insulin sensi-
tivity more than each of the other drugs on the market (ro-
siglitazone and metformin), BGP-15 proved statically superior
to metformin and trended better than rosiglitazone (Fig. 2).
Effect of BGP-15 on insulin sensitivity
in combination with glibenclamide in GK rats
The doses of 10 and 30mg/kg BGP-15 caused a significant
increase in peripheral glucose uptake after 5 days of treat-
ment. BGP-15 (10mg/kg) in combination with glibenclamide
(1.0mg/kg) also increased insulin sensitivity. This combined
effect of BGP-15 and glibenclamide yielded a 97% increase in
glucose infusion rate compared to the control group (Fig. 3).
The effects of BGP-15 on ex vivo relaxation of
aortae obtained from normal and STZ diabetic rats
The decreased maximum vasorelaxation effect of acetyl-
choline in the 9- to 14-week-old STZ diabetic rats was nor-
malized by 5 days of BGP-15 (20 and 50mg/kg) and
rosiglitazone (4mg/kg) treatment. BGP-15 (20mg/kg) pro-
duced a rosiglitazone-like effect both in shape and strength.
Oral administration of BGP-15 in 20- or 50-mg/kg doses
given for 5 days protected against STZ-induced diabetic
changes in the vasorelaxation of the aorta. The effect of BGP-
15 is comparable to that of rosiglitazone (Fig. 4).
Discussion
We evaluated the effect of BGP-15 on insulin sensitivity
in New Zealand white rabbits, Wistar, and GK rats, and
Sprague–Dawley rats in comparison with metformin, ro-
siglitazone, and glibenclamide. As an insulin sensitizer,
BGP-15 outperformed metformin and equaled or superseded
the rosiglitazone drug effect. Additionally, our compound
proved to be effective in increasing insulin sensitivity when
combined with a sulfonylurea agent. Five days of treatment
with multiple different doses clearly showed the insulin-
sensitizing effect of BGP-15 in cholesterol-fed rabbits but not
in normal rabbits, which served as controls. This series of
experiments confirmed that BGP-15 had a beneficial effect
only in the insulin-resistant state.
BGP-15 treatment restored cholinergic vasorelaxation in
aorta obtained from STZ diabetic rats. Vascular smooth
muscle has been recently regarded as a nonclassical insulin-
sensitive tissue. Diabetes impairs endothelium-dependent
FIG. 1. Effect of BGP-15 on insulin sensitivity in normal (A) and cholesterol-fed rabbits (B). The results are expressed as
means – standard deviation (SD) (n= 6 animals per group). (*) Significantly different from the control group, P < 0.05.
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vasorelaxation,5 which can be prevented by rosiglitazone
administration.19 Rosiglitazone may act through increased
nitric oxide (NO) bioavailability.19 It has been demonstrated
that insulin may restore neuronal nitric oxide synthase
(NOS) expression in STZ-induced diabetic rats.20 Moreover,
restoration of acetylcholine vasorelaxation by BGP-15 could
be extinguished by 7-nitro-indazole, an inhibitor of neuronal
NOS.21 These data are in line with our observation that BGP-
15 can induce the expression of neuronal NOS in endothelial
cells and that the BGP-15–induced increase in insulin sensi-
tivity can be abolished by 7-nitro-indazole (unpublished). It
is suggested that BGP-15 may ameliorate diabetes-induced
impairment in vasorelaxation through a neuronal NOS-
dependent mechanism.
FIG. 2. Effect of BGP-15 on insulin sensitivity in Goto–Kakizaki (GK) rats with the hyperinsulinemic euglycemic glucose
clamp (HEGC) method. Data are shown as means – standard deviation obtained with six animals per group. (*) Significantly
different from the control group, P < 0.05. (#) Significantly different from the metformin group, P = 0.025. Insulin sensitivity
improvement with BGP-15 (20mg/kg) compared to rosiglitazone showed a trend to a greater effect with BGP-15 ( p= 0.07),
but the improvement was not statistically significant. Data were analyzed with one-way analysis of variance (ANOVA)
followed by the Student t-test modified according to the Bonferroni method for repeated measures. The comparisons between
treatment groups were calculated with one-way ANOVA pairwise analysis.
FIG. 3. The combined effect of BGP-15 and glibenclamide (Glib) on insulin sensitivity was measured by hyperinsulinemic
euglycemic glucose clamp in Goto–Kakizaki insulin-resistant rats. Data are mean– standard deviation (SD) (n= 7 animals per
group). (*) Significantly different from the control group. (#) Shows a significant difference BGP + glibenclamide versus
glibenclamide alone, P < 0.05. N.S., not significant.
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Hydroximic acid derivatives represent a new class of in-
sulin sensitizers and have entered phase II clinical studies.22
BGP-15 is the first of a new class of insulin sensitizers of the
hydroximic acid derivative family, also known as ‘‘chaper-
one inducers’’ or ‘‘coinducers.’’23–25 Mode of action studies
showed that BGP-15 increases the expression of heat shock
proteins (HSP-90a, HSP-72) and constitutive (c) NOSs (en-
dothelial NOS, neuronal NOS) in cell cultures.26 BGP-15 in-
hibited JNK and increased the level of HSP activity of cNOS
in vitro and in vivo.26,27 Decreased HSP expression is one of
the cellular changes characteristic of diabetes.28–30 Not only
are the levels of HSP72 decreased in T2DM,29–31 but whole-
body glucose utilization is significantly correlated with
HSP72 levels.29 HSP72 acts on insulin sensitivity by inhibit-
ing the inflammatory cascades, which activate the IkB kinase
b (IKK-b) and the inflammatory signaling protein JNK,
which can phosphorylate on tyrosine residues of insulin
receptor substrates and thus inhibit insulin signaling.25,32
Inflammation via the JNK pathway plays a pivotal role in the
development of insulin resistance.33 Furthermore, BGP-15
enhances mitochondrial biogenesis and improves mito-
chondrial dysfunction in pathological metabolic states.34
The HSP chaperone induction effect of hydroximic acid
derivatives is based upon a direct interaction with heat shock
factor-1 (HSF-1).35 This key transcription factor induces ex-
pression of heat shock proteins; they bind to HSF-1 and
stabilize the binding of HSF-1 to its DNA response element.35
The importance of HSF-1, HSPs, and inflammation as they
relate to insulin signaling and T2DM has been recognized
recently.36 The role of HSP-72 in the development of insulin
resistance was demonstrated by Chung et al. in knockout ob/
ob mice. A 15-day-long BGP-15 treatment significantly re-
duced fasting blood glucose and insulin levels and increased
insulin sensitivity as assessed by glucose clamps.11
Where does BGP-15 fit into diabetic therapeutic armamen-
tarium? Insulin resistance appears before the development of
T2DM, a disease that often is accompanied by serious long-
term complications and eventually heavy health economic
consequences due to the tremendous cost of treatment. Nu-
merous large studies have shown that the best way to reduce
the expenditure is through prevention during the ‘‘prediabetic’’
stage or in the early stage of diabetes through change in lifestyle
or pharmaceutical intervention.37 Although changes in lifestyle
have a greater positive effect on the restoration of insulin sen-
sitivity, themore readily accepted insulin sensitizer drugs have
had a big impact not only on the treatment but on disease
prevention as well. Among insulin sensitizers, metformin38
and the TZDs have been tested in these fields. The adverse
effects of PPAR agonists such as TZDs have become an in-
creasing problem in diabetes patients with cardiovascular
disease (CVD). Rosiglitazone therapy was associated with a
significantly increased risk of heart attack [odds ratio
(OR)= 1.43, 95% confidence interval (CI), 1.03–1.98; P= 0.03),
and an even higher risk of death from all cardiovascular dis-
eases (OR= 1.64)8.
Pioglitazone treatment, in contrast, showed significant
protection from all-cause mortality.39 However data regarding
the increased risk in cardiovascular events with TZDs are still
inconsistent. Recently pioglitazone was significantly associ-
ated with an increased risk of bladder cancer.40
Glucagon-like peptide-1–based therapy is gaining wide-
spread use for T2DM, although there are concerns about
risks for pancreatitis and pancreatic and thyroid cancers.
There are also concerns that dipeptidyl peptidase-4 inhibitors
might be oncogenic, given their effects on immune func-
tion,41 but they need further elucidation.
Our results suggest that BGP-15 could be a promising
drug candidate for improving insulin resistance and thus
T2DM. Moreover it could be therapeutic in the prevention
of T2DM and in the treatment of diabetic vascular com-
plications. Our findings support the need for future inves-
tigations of BGP-15 therapy of T2DM patients in phase
II–III studies, administered alone or combined with other
agents.
FIG. 4. The percentage of vasorelaxation by acetylcholine was calculated as 100% of the maximal contraction at steady state
induced by phenylephrine EC50 (phenylephrine concentration producing 50% of maximal tension). Data were expressed as
means – standard error of the mean (SEM), and analyzed with one-way analysis of variance (ANOVA) followed by
multiple comparison post hoc tests. (*) Significantly different from the streptozotocin (STZ) group, P < 0.05.
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